STAREEA Study of STAtins for Reducing Events in the Elderly (STAREE)

Study start date: July 1, 2015

Inclusion Criteria: * Men and women aged ≥70 years living independently in the community * Willing and able to provide informed consent and accept the study requirements (Note: competent physical ability to participate in the trial is assessed using the KATZ ADL questionnaire) Exclusion Criteria: A history of cardiovascular disease (defined as myocardial infarction, stroke, peripheral vascular disease, angina, transient ischaemic attack, coronary artery angioplasty and/or stenting, coronary artery bypass grafting, carotid stenosis, abdominal aortic aneurysm or heart failure), * A history of dementia or a 3MS score \<78 on screening, * A history of diabetes, * Total cholesterol \>7.5 mmol/L, * Moderate or severe chronic kidney disease (persistent proteinuria (Urine albumin:creatinine ratio \>30mg/mmol or Urine protein:creatinine ratios \>45 mg/mmol)45 and/or eGFR \<45ml/min/1.73m2), * Moderate or severe liver disease (persistent elevations of transaminases of more than 3 times the upper limit of the normal laboratory reference range), * Serious inter-current illness likely to cause death within the next 5 years such as terminal cancer or obstructive airways disease, * Current participation in a clinical trial, * Absolute contraindication to statin therapy, * Current use of statin therapy or other lipid lowering therapy for primary prevention and unwilling to stop therapy, * Current long term or permanent use of the following cytochrome P450 (CYP) 3A4 inhibitors : Amiodarone, Boceprevir, Cimetidine, Cyclosporin, Danazol, Fosamprenavir, Indinavir, Lopinavir + Ritonavir, Erythromycin, Fluconazole, Itraconazole, Ketoconazole.